Duh MS - Search Results

1

Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.

Sanchez L, Chari A, Cheng M, Cherepanov D, DerSarkissian M, Huang F, Stull DM, Dabora J, Young M, Noga SJ, Pi S, Zhang M, Banatwala A, Duh MS, Ailawadhi S. Sanchez L, et al. Among authors: duh ms. J Manag Care Spec Pharm. 2023 Nov;29(11):1205-1218. doi: 10.18553/jmcp.2023.23031. Epub 2023 Sep 30. J Manag Care Spec Pharm. 2023. PMID: 37776124 Free PMC article.

Drs Cherepanov, Huang, Dabora, and Noga are current employees of Takeda, while Drs Stull and Young are ex-employees of Takeda; Drs Cherepanov and Huang also own stocks in Takeda. Dr DerSarkissian, Ms Cheng, Ms Zhang, Mr Banatwala, and Dr Duh are employees of …

Drs Cherepanov, Huang, Dabora, and Noga are current employees of Takeda, while Drs Stull and Young are ex-employees of Takeda; Drs Cherepano …

2

Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

DerSarkissian M, Cranmer H, Dabora J, Bocharova I, Cherepanov D, Cheng M, Bhak RH, Duh MS. DerSarkissian M, et al. Among authors: duh ms. Hematology. 2023 Dec;28(1):2156731. doi: 10.1080/16078454.2022.2156731. Hematology. 2023. PMID: 36607147

3

Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program.

Garvey WT, Cheng M, Ramasamy A, Smolarz BG, Park S, Kumar N, Kim N, DerSarkissian M, Bhak RH, Duh MS, Wu M, Hansen S, Young-Xu Y. Garvey WT, et al. Among authors: duh ms. Popul Health Manag. 2023 Feb;26(1):72-82. doi: 10.1089/pop.2022.0227. Epub 2023 Feb 3. Popul Health Manag. 2023. PMID: 36735596

4

Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe.

Huynh L, Hass S, Peyrin-Biroulet L, Duh MS, Sipsma H, Cheng M, Lax A, Nag A. Huynh L, et al. Among authors: duh ms. Crohns Colitis 360. 2022 Jan 27;4(1):otac001. doi: 10.1093/crocol/otac001. eCollection 2022 Jan. Crohns Colitis 360. 2022. PMID: 36777550 Free PMC article.

5

Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL).

Patel H, Wahlstrom SK, DerSarkissian M, Kunzweiler C, Castriota F, Chang R, Gu Y, Guo H, Duh MS, Ryan KJ. Patel H, et al. Among authors: duh ms. Expert Rev Pharmacoecon Outcomes Res. 2023 Jul-Dec;23(6):651-658. doi: 10.1080/14737167.2023.2200167. Epub 2023 Apr 11. Expert Rev Pharmacoecon Outcomes Res. 2023. PMID: 37021518

6

Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor.

Zakharia Y, Huynh L, Du S, Chang R, Pi S, Sundaresan S, Duh MS, Zanotti G, Thomaidou D. Zakharia Y, et al. Among authors: duh ms. Clin Genitourin Cancer. 2023 Oct;21(5):e343-e351. doi: 10.1016/j.clgc.2023.03.017. Epub 2023 Apr 3. Clin Genitourin Cancer. 2023. PMID: 37087399 Free article.

7

Veterans Affairs Prostate Cancer Treatment Sequencing (VAPCaTS): A Real-World Evidence Study of Men with Metastatic Prostate Cancer.

Freedland SJ, De Hoedt AM, DerSarkissian M, Chang R, Satija A, Nguyen C, Park S, Aillaud A, Drea E, Duh MS, Polascik TJ, Szatrowski T. Freedland SJ, et al. Among authors: duh ms. Urol Pract. 2021 Jan;8(1):112-118. doi: 10.1097/UPJ.0000000000000166. Epub 2020 May 29. Urol Pract. 2021. PMID: 37145440

8

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.

Roeker LE, DerSarkissian M, Ryan K, Chen Y, Duh MS, Wahlstrom SK, Hakre S, Yu L, Guo H, Mato AR. Roeker LE, et al. Among authors: duh ms. Blood Adv. 2023 Aug 22;7(16):4291-4301. doi: 10.1182/bloodadvances.2023009739. Blood Adv. 2023. PMID: 37163361 Free PMC article.

9

Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study.

DerSarkissian M, Gu YM, Duh MS, Benson J, Huang SP, Averell C, Vu J, Wang MJ, Bell CF. DerSarkissian M, et al. Among authors: duh ms. ACR Open Rheumatol. 2023 Jun;5(6):318-328. doi: 10.1002/acr2.11550. Epub 2023 May 24. ACR Open Rheumatol. 2023. PMID: 37226045 Free PMC article.

10

Health Care Costs With Sustained Oral Corticosteroid Use in Systemic Lupus Erythematosus.

Huang SP, DerSarkissian M, Gu YM, Duh MS, Wang MJ, Benson J, Vu JD, Averell CM, Bell CF. Huang SP, et al. Among authors: duh ms. Clin Ther. 2023 Jul;45(7):619-626. doi: 10.1016/j.clinthera.2023.04.013. Epub 2023 Jun 2. Clin Ther. 2023. PMID: 37271712 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

312 results

Search Page